APA (7th ed.) Citation

Santos, C., Azuara, D., Viéitez, J. M., Páez, D., Falcó, E., Élez, E., . . . Salazar, R. (2019). Phase II study of high-sensitivity genotyping of KRAS , NRAS , BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: The ULTRA trial. Annals of Oncology, 30(5), 796. https://doi.org/10.1093/annonc/mdz082

Chicago Style (17th ed.) Citation

Santos, C., et al. "Phase II Study of High-sensitivity Genotyping of KRAS , NRAS , BRAF and PIK3CA to Ultra-select Metastatic Colorectal Cancer Patients for Panitumumab Plus FOLFIRI: The ULTRA Trial." Annals of Oncology 30, no. 5 (2019): 796. https://doi.org/10.1093/annonc/mdz082.

MLA (9th ed.) Citation

Santos, C., et al. "Phase II Study of High-sensitivity Genotyping of KRAS , NRAS , BRAF and PIK3CA to Ultra-select Metastatic Colorectal Cancer Patients for Panitumumab Plus FOLFIRI: The ULTRA Trial." Annals of Oncology, vol. 30, no. 5, 2019, p. 796, https://doi.org/10.1093/annonc/mdz082.